Invivyd (NASDAQ:IVVD) Posts Earnings Results

Invivyd (NASDAQ:IVVD - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10, Zacks reports. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million.

Invivyd Stock Down 1.9 %

Shares of IVVD stock traded down $0.01 during mid-day trading on Monday, hitting $0.72. 2,522,127 shares of the stock were exchanged, compared to its average volume of 4,232,478. Invivyd has a 52-week low of $0.35 and a 52-week high of $4.74. The company has a market cap of $86.60 million, a PE ratio of -0.37 and a beta of 0.09. The firm has a fifty day moving average of $0.99 and a 200 day moving average of $0.87.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 83,817 shares of the company's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18. Following the completion of the transaction, the director now directly owns 3,340,520 shares in the company, valued at approximately $1,803,880.80. This represents a 2.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 17.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IVVD shares. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Invivyd in a report on Monday, February 24th. D. Boral Capital reiterated a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $7.89.

Remove Ads

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.